<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085265</url>
  </required_header>
  <id_info>
    <org_study_id>148-2013</org_study_id>
    <nct_id>NCT02085265</nct_id>
  </id_info>
  <brief_title>Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients</brief_title>
  <acronym>SARTAN-AD</acronym>
  <official_title>The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimerâ€™s Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weston Brain Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To conduct a proof of concept study in patients with mild to moderate Alzheimer's Disease who
      have treated hypertension, in order to determine if there is less global brain atrophy over
      one year, as measured by ventricular enlargement as a primary outcome measure, when patients
      are randomized to treatment with an angiotensin receptor blocker compared to an Angiotensin
      Converting Enzyme inhibitor (ACEI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study uses a simple validated measure of brain atrophy as a surrogate marker in a
      repurposing effort that could recast an antihypertensive medication as a cognitive
      enhancer/neuroprotective agent and possibly as a drug of choice for Alzheimer patients and
      patients at risk for AD. If the proof of concept result is positive, a larger study would be
      warranted with potential practice-changing impact.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventricular enlargement</measure>
    <time_frame>12 months</time_frame>
    <description>Change in ventricular size, on 3D T1 MR imaging, after 12 months of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Change in blood pressure (BP) measurements after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Vital signs</measure>
    <time_frame>12 months</time_frame>
    <description>Change in vital sign (heart rate, pulse) measurements after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Electrolytes</measure>
    <time_frame>12 months</time_frame>
    <description>Change in electrolyte measurements (Na, K) after 12 months of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse events and serious adverse events over 12 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hippocampal volume</measure>
    <time_frame>12 months</time_frame>
    <description>Change in hippocampal volume measurements after 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grey/White matter volume</measure>
    <time_frame>12 months</time_frame>
    <description>Volume of grey and white matter in the cingulate, parietotemporal and dorsolateral frontal regions after 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive and functional measures</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Neuropsychiatric Measures</measure>
    <time_frame>6 &amp; 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 &amp; 12 months</time_frame>
    <description>Change in caregiver burden and health-related quality of life after treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment responsiveness of Diffusion Tensor Imaging (DTI)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Treatment responsiveness of resting state functional MRI (rsfMRI)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perindopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perindopril</intervention_name>
    <description>Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)</description>
    <arm_group_label>Perindopril</arm_group_label>
    <other_name>Coversyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)</description>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>teva-telmisartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Diagnosis of Probable AD dementia or Possible AD dementia due to concomitant
             cerebrovascular disease (as permitted by the study exclusion criteria), using the 2011
             McKhann criteria63

          2. Previous brain MRI or CT scan to rule out exclusionary pathology, such as cortical
             stroke, tumour, subdural hematomas, malformations, severe periventricular white matter
             disease, etc., and absence of stepwise decline since the previous scan.

          3. Age 50 years or older

          4. Established diagnosis of hypertension and on at least one antihypertensive medication

          5. Standardized Mini Mental State Examination (SMMSE) score of 16-27 at screening visit

          6. Sufficient hearing and vision to participate in testing as per investigator's
             judgement

          7. Sufficient fluency in English to be able to complete language and other cognitive
             tests

          8. At least 8 years of education

          9. A study partner who in the opinion of the study investigator has regular interaction
             with the patient, can be present for all clinic visits, can provide a collateral
             history and can assist in compliance with study procedures

         10. On a cholinesterase inhibitor (ChEI) and/or memantine (unless unable to tolerate);
             dose must be stable for 30 days prior to randomization

         11. HbA1C &lt;8.5%. Patients with stable type II diabetes are eligible for the study if there
             have been no severe hypoglycemic events requiring third party intervention (e.g.
             emergency department visit) for 6 months prior to randomization

         12. Patients on medications for vascular risk factors (e.g., hypertension, cholesterol,
             diabetes) or on psychotropic medications must be on a stable dose for 30 days prior to
             randomization.

        Exclusion criteria

          1. Intolerance, or any contraindications, to study medications

          2. Familial autosomal dominant form of Alzheimer's disease

          3. Creatinine clearance less than or equal to 30ml/min

          4. Serum potassium &gt; 5.5 mEq/L

          5. ALT &gt; the upper limit of normal (ULN)

          6. History of angioedema

          7. Co-morbid acute or chronic conditions (including type I diabetes mellitus, stroke,
             other neurological conditions such as Parkinson's disease, and psychiatric disorders,
             and severe or unstable medical conditions) that could confound assessments or would,
             in the judgment of the investigator, make the subject inappropriate for entry into
             this study

          8. Any of the following findings on previous CT/MRI or on screening MRI:

               1. Severe periventricular white matter disease (Fazekas score 3);

               2. Cortical or subcortical infarct &gt;1.5 cm in diameter;

               3. More than 1 cortical infarct;

               4. More than 2 subcortical lacunar infarcts (&lt;1.5 cm diameter) in the basal ganglia
                  or white matter;

               5. Strategic lacunar infarct in the thalamus;

               6. Intracerebral hemorrhage (any size);

               7. Any cortical superficial siderosis;

               8. More than 5 cerebral microbleeds.

          9. Inability to perform the study procedures, including claustrophobia or
             contraindications for MRI

         10. Currently on or has taken an angiotensin receptor blocker within 12 months of
             randomization visit

         11. Resides in a nursing home (participants who reside in retirement homes may be included
             if they have a study partner who meets inclusion criterion #9)

         12. Current major depression by clinical history or score greater than 18 on the Cornell
             Scale for Depression in Dementia

         13. Documented potential cardiac source of brain infarction such as mechanical valve or
             any type of atrial fibrillation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Black, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krista Lanctot, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Black, MD</last_name>
    <phone>416.480.4551</phone>
    <email>sandra.black@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ljubica Zotovic, MD</last_name>
    <phone>416.480.6100</phone>
    <phone_ext>3004</phone_ext>
    <email>ljubica.zotovic@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramnik Sekhon</last_name>
      <phone>403-210-7737</phone>
      <email>ramnik.sekhon@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Anna Charlton</last_name>
      <phone>403-210-6164</phone>
      <email>acharlto@ucalgary.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Lethbridge</name>
      <address>
        <city>Lethbridge</city>
        <state>Alberta</state>
        <zip>T1K 6T5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keiko McCreary, PhD</last_name>
      <phone>403-394-3985</phone>
      <email>keiko.mccreary2@uleth.ca</email>
    </contact>
    <investigator>
      <last_name>John Kennedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Sutherland, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mannie Fan</last_name>
      <phone>604-822-0550</phone>
      <email>mannie.fan@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Robin Hsiung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Connolly</last_name>
      <phone>289-440-1205</phone>
      <email>connollyb@HHSC.CA</email>
    </contact>
    <investigator>
      <last_name>Demetrios (James) Sahlas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkwood Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 4R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Borrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South East Toronto Family Health Team</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus Law, MD</last_name>
      <phone>416.699.7775</phone>
      <email>marcus.law@utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Marcus Law, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Memory and Aging</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mayrose Cornejo</last_name>
      <phone>416-663-6897</phone>
      <phone_ext>24</phone_ext>
      <email>mcornejo@memorycentre.ca</email>
    </contact>
    <contact_backup>
      <last_name>Josephine Accarrino</last_name>
      <phone>416-663-6897</phone>
      <phone_ext>21</phone_ext>
      <email>jaccarrino@memorycentre.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni Marotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferhana Dhira</last_name>
      <phone>416-480-6103</phone>
      <email>ferhana.dhira@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ljubica Zotovic</last_name>
      <phone>416-480-6100</phone>
      <phone_ext>3004</phone_ext>
      <email>ljubica.zotovic@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sandra Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Corinne Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baycrest Health Sciences</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brad Pugh</last_name>
      <phone>406.785.2500</phone>
      <phone_ext>6207</phone_ext>
      <email>b.pugh@baycrest.org</email>
    </contact>
    <investigator>
      <last_name>Morris Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apoorva Bhandari</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>33532</phone_ext>
      <email>Apoorva.Bhandari@camh.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lina Chiuccariello</last_name>
      <phone>416-535-8501</phone>
      <phone_ext>30409</phone_ext>
      <email>Lina.Chiuccariello@camh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjeev Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Waterloo</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Middleton, PhD</last_name>
      <phone>519-888-4567</phone>
      <phone_ext>33045</phone_ext>
      <email>lmiddlet@uwaterloo.ca</email>
    </contact>
    <investigator>
      <last_name>Laura Middleton, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Heckman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>March 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2014</study_first_posted>
  <last_update_submitted>November 23, 2017</last_update_submitted>
  <last_update_submitted_qc>November 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Sandra E Black</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Perindopril</keyword>
  <keyword>Telmisartan</keyword>
  <keyword>Brain atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Perindopril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

